Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Arcutis Biotherapeutics, Inc.

Clinical trials sponsored by Arcutis Biotherapeutics, Inc., explained in plain language.

Arcutis Biotherapeutics, Inc. ARQT NASDAQ

A dermatology-focused biopharmaceutical company developing topical therapies for skin conditions.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Completed 5

New eczema drug enters first human tests

Symptom relief Recruiting now

This early-stage trial is testing a new injectable drug called ARQ-234 in healthy volunteers and people with moderate to severe eczema. The main goals are to check safety and how the body processes the drug, while also looking for early signs that it might improve eczema symptoms…

Phase: PHASE1 • Sponsor: Arcutis Biotherapeutics, Inc. • Aim: Symptom relief

Last updated Jun 27, 2026 12:37 UTC